Frederick Trent, MD
Pulmonary Disease · Jacksonville, FLNPI 1982677712
Payments from drug & device makers
Across 448 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Boehringer Ingelheim$635
- Regeneron Healthcare Solutions, Inc.$457
- Philips North America LLC$452
- Sanofi$314
- plus $2K from 30 others
What the payments were for
- Food & beverage$7,565100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 112 | $1,802 |
| AstraZeneca | 91 | $1,660 |
| Boehringer Ingelheim | 37 | $635 |
| Regeneron Healthcare Solutions, Inc. | 19 | $457 |
| Philips North America LLC | 53 | $452 |
| Sanofi | 17 | $314 |
| Novartis | 14 | $248 |
| Mylan Specialty L.p. | 12 | $216 |
| Electromed, Inc. | 9 | $166 |
| Merck | 5 | $113 |
| Verona Pharma, Inc. | 4 | $108 |
| Baxter Healthcare | 6 | $105 |
| Viatris Specialty LLC | 4 | $94 |
| AbbVie(2 entities) | 5 | $93 |
| Inogen, Inc. | 6 | $93 |
| Axsome Therapeutics, Inc. | 4 | $92 |
| Inspire Medical Systems, Inc. | 1 | $91 |
| Insmed, Inc. | 6 | $86 |
| Grifols USA, LLC | 4 | $78 |
| Actelion Pharmaceuticals US, Inc. | 4 | $77 |
| Shionogi Inc | 4 | $75 |
| Sunovion Pharmaceuticals Inc. | 5 | $67 |
| Circassia Inc. | 4 | $58 |
| Genentech USA, Inc. | 3 | $47 |
| Mallinckrodt Hospital Products Inc. | 2 | $46 |
| Advanced Respiratory, Inc | 3 | $45 |
| United Therapeutics Corporation | 2 | $39 |
| Lilly USA, LLC | 2 | $38 |
| Pulmonx Corporation | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 1 | $32 |
| Gilead | 2 | $30 |
| Harmony Biosciences LLC | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| 3b Medical, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Amgen | 1 | $15 |
How this compares
$7,590 in reported general payments places this provider in the 60th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 360 | $309,046 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $78,663 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $72,057 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 100 | $65,173 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 63 | $42,710 |
| Spiriva RespimatTiotropium Bromide | 60 | $37,165 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $18,992 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $9,284 |
| SymbicortBudesonide/Formoterol Fumarate | 35 | $7,986 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 15 | $6,933 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 236 | $5,279 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $5,036 |
| Wixela InhubFluticasone Propion/Salmeterol | 28 | $3,586 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,335 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $3,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,802 | $455,560630 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $1,660 | $93,582167 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $635 | $79,875123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Jacksonville
- Charles BurgerJacksonville$5.6M
- Abubakr BajwaJacksonville$1.4M
- Jennifer FultonJacksonville$791K
- Sebastian Fernandez-BussyJacksonville$559K
- Remzi BagJacksonville$556K
- Jose Soto SotoJacksonville$549K
- Augustine LeeJacksonville$533K
- Jorge MalleaJacksonville$478K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.